TRIM13, tripartite motif containing 13, 10206

N. diseases: 275; N. variants: 1
Disease: Multiple Myeloma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.100 GeneticVariation disease BEFREE Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma. 31005597 2019
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.100 Biomarker disease BEFREE Tripartite Motif Containing 13 (TRIM13), a member of TRIM proteins, is deleted in multiple tumor types, especially in B-cell chronic lymphocytic leukemia and multiple myeloma. 31357025 2019
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.100 Biomarker disease BEFREE CAR T cell therapies for MM are at an early stage of clinical development. 30730071 2019
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.100 Biomarker disease BEFREE These results demonstrate that the CD38-CAR-Ts constructed with the anti-CD38 nanobody are a promising approach for the treatment of multiple myeloma. 30185037 2018
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.100 Biomarker disease BEFREE This is a review on the emerging field of adoptively transferred engineered T cell based approaches, with an in-depth focus on chimeric antigen receptors (CAR) targeting multiple myeloma. 29105517 2018
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.100 Biomarker disease BEFREE Sending CAR T Cells After Multiple Myeloma. 28588060 2017
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.100 Biomarker disease BEFREE We also describe the role of agents targeting PD-1 axis and chimeric antigen receptor T (CAR-T) cells in the treatment of MM. 27863374 2017
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.100 Biomarker disease BEFREE Expert opinion: Early results of clinical studies using CAR T cells or TCR- engineered T cells in relapsed and refractory MM are particularly exciting, indicating the potential of long-term disease control or even cure. 28857616 2017
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.100 Biomarker disease BEFREE With several novel agents in the preclinical and early clinical pipeline, among those novel CD38 and BCMA mAbs, immune checkpoint inhibitors, as well as ricolinostat, selinexor, venetoclax, CAR-T cells, and vaccines, further advances in MM patient outcome are expected in the near future. 28604120 2017
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.100 GeneticVariation disease BEFREE We can therefore exclude that common genetic variants in the xenobiotic transport and metabolism regulator genes PXR and CAR affect MM risk. 23303387 2013
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.100 Biomarker disease BEFREE Although this data does not support a role of TRIM13 as a TSG, it substantiates important roles of TRIM13 in MM tumour survival and proliferation, underscoring its potential role as a novel target for therapeutic intervention. 23647456 2013
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.100 Biomarker disease BEFREE However, a role for RFP2 in the pathogenesis of MM cannot yet be excluded, given that alternative mechanisms such as haploinsufficiency remain possible. 12461754 2003